Investigating VIP236 in a dose escalation cohort in subjects with advanced solid tumor cancer
VIP236 is a small molecule drug conjugate (SMDC) consisting of an alpha v beta 3 (αVβ3) integrin binder linked to an optimized camptothecin (CPT) compound (VIP126), which is released by the enzyme neutrophil elastase (NE) in the tumor microenvironment (TME).
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
